Heather Franklin
Vermögen: 273 993 $ am 31.05.2026
Vermögen: 273 993 $ am 31.05.2026
Heather L.
Franklin is the founder of Blaze Bioscience, Inc., founded in 2011, serving as President, Chief Executive Officer & Director since 2013.
Current jobs include Executive Chairman & President at Presage Biosciences, Inc., and Independent Director at XOMA Royalty Corp.
since 2021.
Former jobs include Director at Life Science Washington from 2020 to 2024, Senior Manager-Research Operations Program at Amgen, Inc., Head-Project Management at AmpliPhi Biosciences Corp., and SVP-Business Development & Alliance Management at ZymoGenetics, Inc. from 2008 to 2010.
Education includes undergraduate studies at The University of North Carolina at Charlotte and an MBA from The Wharton School of the University of Pennsylvania.
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
XOMA ROYALTY CORPORATION 0,05 % | 05.06.2026 | 6 569 ( 0,05 % ) | 273 993 $ | 31.05.2026 |
| Unternehmen | Position | Beginn |
|---|---|---|
| XOMA ROYALTY CORPORATION | Direktor/Vorstandsmitglied | 06.08.2021 |
Blaze Bioscience, Inc.
Blaze Bioscience, Inc. Medical/Nursing ServicesHealth Services Develops products for cancer patients | Gründer | 01.01.2011 |
Presage Biosciences, Inc.
Presage Biosciences, Inc. Pharmaceuticals: MajorHealth Technology Engages in development of novel drugs for treatment of cancers | Vorsitzender | - |
| Unternehmen | Position | Ende |
|---|---|---|
Washington Biotechnology & Biomedical Association
Washington Biotechnology & Biomedical Association Miscellaneous Commercial ServicesCommercial Services Operates as a nonprofit trade association that supports and promotes the life sciences industry | Direktor/Vorstandsmitglied | 01.01.2024 |
ZymoGenetics, Inc.
ZymoGenetics, Inc. Pharmaceuticals: MajorHealth Technology Develops protein based drugs | Corporate Officer/Principal | 01.12.2010 |
AmpliPhi Biosciences Corp.
AmpliPhi Biosciences Corp. BiotechnologyHealth Technology Develops and commercializes novel bacteriophage-based therapeutics | Corporate Officer/Principal | - |
| AMGEN INC. | Corporate Officer/Principal | - |
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
| Private Unternehmen | 10 |
|---|---|
Amgen, Inc.
Amgen, Inc. BiotechnologyHealth Technology Discovers, develops, manufactures and delivers human therapeutics | Health Technology |
AmpliPhi Biosciences Corp.
AmpliPhi Biosciences Corp. BiotechnologyHealth Technology Develops and commercializes novel bacteriophage-based therapeutics | Health Technology |
XOMA Royalty Corp.
XOMA Royalty Corp. Pharmaceuticals: MajorHealth Technology Discovers and develops antibody therapeutics | Health Technology |
ZymoGenetics, Inc.
ZymoGenetics, Inc. Pharmaceuticals: MajorHealth Technology Develops protein based drugs | Health Technology |
Presage Biosciences, Inc.
Presage Biosciences, Inc. Pharmaceuticals: MajorHealth Technology Engages in development of novel drugs for treatment of cancers | Health Technology |
Blaze Bioscience, Inc.
Blaze Bioscience, Inc. Medical/Nursing ServicesHealth Services Develops products for cancer patients | Health Services |
University of Washington
University of Washington Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Washington Biotechnology & Biomedical Association
Washington Biotechnology & Biomedical Association Miscellaneous Commercial ServicesCommercial Services Operates as a nonprofit trade association that supports and promotes the life sciences industry | Commercial Services |
The University of North Carolina at Charlotte
The University of North Carolina at Charlotte Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
The Wharton School of the University of Pennsylvania
The Wharton School of the University of Pennsylvania Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Bitte wählen Sie Ihre Ausgabe
Alle länderspezifischen Finanzinformationen